Actively Recruiting
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
Led by IWK Health Centre · Updated on 2024-06-21
100
Participants Needed
9
Research Sites
142 weeks
Total Duration
On this page
Sponsors
I
IWK Health Centre
Lead Sponsor
B
BC Children's Hospital Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Background: Among preterm infants, those born at a gestational age less than 26 weeks are considered the most vulnerable with a high risk of short- and long-term health problems that include chronic lung disease, brain bleeds, gut injury, kidney failure and death. Patent ductus arteriosus (PDA) is the most common heart condition with almost 70% preterm infants in this gestational age group being diagnosed with a PDA. Though many PDAs spontaneously resolve on their own, research suggests that if the PDA persists, it may contribute to a number of these short- and long-term health problems. Non-steroidal anti-inflammatory medications such as ibuprofen are commonly used to treat a PDA. Such drugs can also have harmful effects on the gut and kidneys of extremely preterm infants. Therefore, we are unsure if early treatment of a symptomatic PDA in this age group is at all beneficial. Given the wide variation in PDA treatment approaches in this age group, a randomized trial design, where extremely preterm infants with a symptomatic PDA are randomly assigned to early treatment or no early treatment, is essential to address this question. Purpose of the study: The overall purpose of this pilot study is to assess the feasibility of conducting a large study to explore the following research question: In preterm infants born \<26 weeks' gestation, is a strategy of selective early medical treatment of a symptomatic PDA better than no treatment at all in the first week of life? The main feasibility objectives of this study are: 1. To assess how many eligible infants can be enrolled in the study 2. To assess how many enrolled infants properly complete the study protocol Importance: To our knowledge this will be the first study on PDA management in preterm infants that specifically aims to enroll preterm infants born at \<26 weeks of gestational age who are at the highest risk for PDA-related problems but have been mostly under-represented in previous PDA studies.
CONDITIONS
Official Title
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Preterm infants less than 26 completed weeks (up to and including 25 weeks and 6 days) of gestation
You will not qualify if you...
- No PDA on initial screening echocardiography
- Congenital heart disease excluding patent foramen ovale, atrial septal defect, or ventricular septal defect smaller than 2mm
- Presence of other major congenital anomalies
- Decision to withhold or withdraw care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Children's Hospital of Orange County
Orange, California, United States, 92868
Actively Recruiting
2
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California, United States, 92123
Terminated
3
OU College of Medicine, University of Oklahoma
Oklahoma City, Oklahoma, United States, 73117
Actively Recruiting
4
Stollery Children's Hospital
Edmonton, Alberta, Canada
Actively Recruiting
5
British Columbia Women's Hospital
Vancouver, British Columbia, Canada
Actively Recruiting
6
IWK Health Center
Halifax, Nova Scotia, Canada, B3K 6R8
Actively Recruiting
7
Mount Sinai Hospital
Toronto, Ontario, Canada
Withdrawn
8
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Withdrawn
9
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, Canada
Actively Recruiting
Research Team
S
Souvik Mitra, MD, MSc
CONTACT
A
Amish Jain, MBBS, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here